ASXL1 and acute myeloid leukemia: One patient carrying ASXL1, SETBP1 and RUNX1 mutations evolved to AML within seven years of the AA diagnosis; this patient was diagnosed with NSAA at the age of 47 and received oral cyclosporine therapy for two years, but the disease relapsed after discontinuation of the drug.